Recent advances in developing biosensing based platforms for neonatal sepsis

Balayan, Sapna; Chauhan, Nidhi; Chandra, Ramesh; Kuchhal, N. K.; Jain, Utkarsh

doi:10.1016/j.bios.2020.112552

Cited by 37 publications

(28 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many new biomarker detection techniques have become available in recent years, such as surface plasmon resonance, quartz crystal microbalance, and electrochemical measurements. 7 The LODs of surface plasmon resonance, quartz crystal microbalance and electrochemical measurements are measured in the range of ng/mL and pg/mL, 36 whereas the LOD of the IMR assay is measured in pg/mL to fg/mL (the LOD values for assaying CRP and PCT were 2.26×10 −4 ng/mL and 9.97×10 −6 ng/mL in this study). Moreover, the IMR assay can measure dozens of samples at the same time, and pre-processing for the IMR method is simple and only requires mixing the sample with the appropriate reagent before assaying.…”

Section: Discussionmentioning

confidence: 80%

“…Previous studies have demonstrated that various potential biomarkers can be used to effectively screen for neonatal sepsis, including C-reactive protein (CRP) and procalcitonin (PCT). 6 , 7 CRP and PCT are acute phase reactants which are widely used in current clinical practice to detect systemic inflammation and infection. CRP is synthesized in the liver in response to proinflammatory cytokines (interleukin-1β [IL-1β], IL-6, and tumor necrosis factor [TNF]), and it is released into the systemic circulation after inflammation or infection.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bio-Functionalized Magnetic Nanoparticles for the Immunoassay of C-Reactive Protein and Procalcitonin in Cervicovaginal Secretions of Pregnant Women with Preterm Prelabor Rupture of Membranes to Predict Early-Onset Neonatal Sepsis

Ang¹,

Chen²,

Sun³

et al. 2022

IJN

View full text Add to dashboard Cite

Purpose Early-onset sepsis is a major cause of neonatal morbidity and mortality. C-reactive protein (CRP) and procalcitonin (PCT) are acute phase reactants related to infection. The aim of this study was to explore the feasibility of measuring CRP and PCT concentrations in cervicovaginal secretions of pregnant women with preterm prelabor rupture of membranes (PPROM) using an immunomagnetic reduction (IMR) assay to predict early-onset neonatal sepsis. Patients and Methods This prospective study was performed at Mackay Memorial Hospital, Taipei, Taiwan from February 2015 to January 2018. Pregnant women with PPROM between 22 and 34 weeks of gestation were recruited. CRP and PCT concentrations in cervicovaginal secretions were measured using an IMR assay. Results Thirty-five cervicovaginal secretion samples were obtained. After excluding two neonatal deaths, early-onset neonatal sepsis was diagnosed in 15 of the 33 surviving neonates. There was no significant relationship between cervicovaginal secretion CRP level and neonatal sepsis; however, cervicovaginal secretion PCT levels were significantly higher in the neonatal sepsis group than in the non-sepsis group (45.99 vs 9.54 ng/mL, P = 0.039). Receiver operating characteristic (ROC) curve analysis revealed a PCT cut-off level of 20.60 ng/mL to predict early-onset sepsis, and the area under the ROC curve was 0.71 (95% confidence interval 0.52 to 0.90, P = 0.039), with sensitivity and specificity of 73.3% and 77.8%, respectively. Conclusion Measuring the concentration of PCT in cervicovaginal secretions with an IMR assay can predict early-onset sepsis in neonates born to mothers with PPROM.

show abstract

Section: Discussionmentioning

confidence: 80%

Section: Introductionmentioning

confidence: 99%

Bio-Functionalized Magnetic Nanoparticles for the Immunoassay of C-Reactive Protein and Procalcitonin in Cervicovaginal Secretions of Pregnant Women with Preterm Prelabor Rupture of Membranes to Predict Early-Onset Neonatal Sepsis

Ang¹,

Chen²,

Sun³

et al. 2022

IJN

View full text Add to dashboard Cite

show abstract

“…[3] Furthermore, changes in the concentration of CRP in human blood at ultra-low levels induce malignancy, hypersensitivity reactions, trauma, allograft rejection, and necrosis. [4][5][6] The cardiovascular events in association with elevated levels of CRP in blood and serum along with traditional risk factors alarms need to be addressed in the future. [6,7] Because of these effects, the Centres for Disease Control and Prevention affirmed that CRP levels of 1.0 mg L À 1 are sufficient to increase the risk of cardiovascular disease.…”

Section: Introductionmentioning

confidence: 99%

“…Cardiac diseases like acute inflammatory disease, peripheral arterial disease, and myocardial infarction cause CRP level variations [3] . Furthermore, changes in the concentration of CRP in human blood at ultra‐low levels induce malignancy, hypersensitivity reactions, trauma, allograft rejection, and necrosis [4–6] . The cardiovascular events in association with elevated levels of CRP in blood and serum along with traditional risk factors alarms need to be addressed in the future [6,7] .…”

Section: Introductionmentioning

confidence: 99%

Development of an Electrodeposited Graphene Quantum Dot Electrode for the Electrochemical Detection of C‐Reactive Protein (CRP) Biomarker

et al. 2022

View full text Add to dashboard Cite

C-reactive protein (CRP) is a potential cardiac biomarker whose levels fluctuate in response to cardiac diseases. In particular, the severity of cardiovascular disease can be associated with the level of CRP, emphasizing the necessity for a highly sensitive biosensor capable of detecting CRP at ultralow levels in a short period of time. In this study, we used a facile pyrolysis method to synthesize graphene quantum dots (GQDs) with a diameter of 2.2 nm. Then, to fabricate the Au/GQDs/anti-CRP electrode, GQDs were electrodeposited successfully on the surface of the bare Au electrode to provide a nano-interfaced matrix platform for effective anti-CRP immobilization. Cyclic voltammetry was used to investigate the contact between anti-CRP and CRP in the Fe(CN) 6 3À /4À as a mediator. The recorded current signal from differential pulse voltammetry measurements shows that the associative interaction between the anti-CRP and CRP is efficiently induced. Furthermore, the Figureure of merits of the developed sensor, including the sensory response of < 50 s with a high sensitivity of 58 μA ng À 1 mL À 1 cm À 2 and a low detection capability of 0.104 ng mL À 1 (n = 3), suggests that it is a potential candidate for point-of-care testing. And the fabricated Au/GQDs/anti-CRP biosensor were used to sense CRP in an artificial serum (ringer lactate) solution.

show abstract

“…9,10 In neonatal drug resistance, Escherichia coli showed resistance to β-lactam antibiotics and aminoglycosides; group B streptococci were resistant to penicillin; Listeria monocytogenes were resistant to cephalosporins and vancomycin; Staphylococcus aureus and coagulase-negative staphylococci were not sensitive to vancomycin and methicillin. 11,12 This drug resistance can harm sepsis prognosis and almost double mortality.…”

Section: Introductionmentioning

confidence: 99%

The Potential of Drug Delivery Nanosystems for Sepsis Treatment

Shi¹,

Zhu²,

Wu³

et al. 2021

JIR

View full text Add to dashboard Cite

Sepsis is a major immune response disorder caused by infection, with very high incidence and mortality rates. In the clinic, sepsis and its complications are mainly controlled and treated with antibiotics, anti-inflammatory, and antioxidant drugs. However, these treatments have some shortcomings, such as rapid metabolism and severe side effects. The emergence of drug delivery nanosystems can significantly improve tissue permeability, prolong drugs' circulation time, and reduce side effects. In this paper, we reviewed recent drug delivery nanosystems designed for sepsis treatment based on their mechanisms (anti-bacterial, anti-inflammatory, and antioxidant). Although great progress has been made recently, clinical practice transformation is still very difficult. Therefore, we also discussed key obstacles, including tissue distribution, overcoming bacterial resistance, and single treatment modes. Finally, a rigorous optimization of drug delivery nanosystems is expected to present great potential for sepsis therapy.

show abstract

Recent advances in developing biosensing based platforms for neonatal sepsis

Cited by 37 publications

References 106 publications

Bio-Functionalized Magnetic Nanoparticles for the Immunoassay of C-Reactive Protein and Procalcitonin in Cervicovaginal Secretions of Pregnant Women with Preterm Prelabor Rupture of Membranes to Predict Early-Onset Neonatal Sepsis

Bio-Functionalized Magnetic Nanoparticles for the Immunoassay of C-Reactive Protein and Procalcitonin in Cervicovaginal Secretions of Pregnant Women with Preterm Prelabor Rupture of Membranes to Predict Early-Onset Neonatal Sepsis

Development of an Electrodeposited Graphene Quantum Dot Electrode for the Electrochemical Detection of C‐Reactive Protein (CRP) Biomarker

The Potential of Drug Delivery Nanosystems for Sepsis Treatment

Contact Info

Product

Resources

About